IMB001, the company’s patented strain, is a new live biotherapeutic candidate with unique polysaccharides, called RHP, on the surface.
Effect of T cell proliferation
IMB001 activates macrophages in the intestines, which travel to lymph nodes, activating T cells and inducing proliferation of effector CD8+IFNg+ T cells. These activated T cells travel to cancer tissue areas, eliminating cancer cells.
Sequestration of iron ions in the tumor microenvironment
While macrophages exposed to IMB001 secrete inflammatory cytokines, such as IFNg, inhibit cancer cell growth and induce apoptosis by depleting iron ions essential for cancer cell growth in the tumor microenvironment.
Synergetic effect with immuno-oncology drugs
Coadministration of IMB001 with immuno-oncology drug brings a synergistic effect to reduce the growth of cancer cells.